BTS statement on malignant mesothelioma in the UK, 2007.
about
Malignant mesotheliomaClinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusionsFactors that impact susceptibility to fiber-induced health effectsGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaModern management of malignant pleural mesotheliomaA multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trialPerformance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.Malignant pleural mesothelioma: an epidemiological perspectiveThe role of interleukin-6 in malignant mesotheliomaPleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions?Pleural mesothelioma surveillance: validity of cases from a tumour registryProtocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.What is the survival after surgery for localized malignant pleural mesothelioma?Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos.Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest GrouWhat is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK.Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).Asbestos-related pleuropulmonary diseases: benign and malignant.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Pleural procedures in the management of malignant effusions.Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma.Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.Simultaneous bilateral spontaneous hydropneumothorax: a rare presentation of bilateral malignant pleural mesothelioma.Working with asbestos and the possible health risks.p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.Pleural effusion: what lies underneath?Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.Malignant mesothelioma: Canadian perspective and research directions.Asbestos Ban in Italy: A Major Milestone, Not the Final Cut.Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.Malignant mesothelioma as a difficult interdisciplinary problem.Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma.Should cytology be an acceptable means of diagnosing malignant mesothelioma?New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
P2860
Q21202901-9125C70B-A0B8-470D-985B-D04CBADBC9A5Q28238665-9A616307-DBC9-4C32-AA2A-53A667A4C504Q28389535-9DD858D7-93A6-4CC3-B7B0-AAE6EBE01EBBQ28394028-BFDBAE70-EC68-4412-A5A8-1652D40D6ACBQ29248127-EE9491F2-64F3-4C87-B6D4-00F4C9F7C7F3Q30588623-77690539-257E-4236-813E-F591D1173663Q30614413-2AFCEE6C-8823-42C4-BA4B-ABBC7F44F8C1Q30790098-0F6210A0-E9E2-4D36-A820-AF8165316C1FQ33815929-DB16BD8A-A59B-45EA-A8FF-302C9AF00EA9Q34130373-FCC79FE8-E547-4373-A73D-55F74C7A172CQ34366730-4B93AAC5-E2A1-4D65-8171-7299CF2F56E8Q35200628-858CA8BA-551A-4B50-930D-8B3DAC5C9ECDQ35739564-6EEF6C06-9665-41A7-9403-89CC0B665A7EQ36027122-1EFBB6E7-2E9D-493A-BA95-4E96DDB80B1EQ36526737-373A8FAB-D7A2-47CE-A5DA-2123700AB8EDQ36685838-0BCABA41-177E-4CEF-BEC4-992E61BCB0D0Q36766690-55533CC2-D9F6-46C0-9D60-3920979446E1Q36820998-0589358A-034C-4467-8853-493B5CAB2FC9Q36990070-134E754F-5CBD-4506-AF7E-C7E772F84B3DQ37252039-3D296F2F-192F-466F-A02D-1778F5CB00F4Q37277434-7EDA9F5B-871C-4F8C-B822-F50C94B3D677Q38018217-E680F320-4EF2-4141-BA7B-BDD194EF6CDAQ38118298-AAA91106-C856-4F8A-B4E7-7DB5A41847BFQ39135624-B1E64979-15F9-43CC-A524-30A937C9C11DQ40166240-6EAD8FD4-A36A-4771-8704-0CA1DBCA27A1Q40336711-853D14E3-3A54-4462-B630-7663AF6DD284Q41371658-8F6BE699-8386-48D8-8BD8-8F8C87F375D8Q41624155-7B533E5C-98BB-469B-AED9-DD812D8F04C7Q41849387-F8E25DD5-E98D-4671-8075-65056C68B5FFQ42582696-CCB2449A-5BBB-4ABC-B348-87E54628EE0EQ45327540-2E8C6FEA-1A9C-4A6F-A029-8F27DEEC7623Q47096401-886CB92E-9E00-4EB6-987F-E630EC0D1DDAQ47098675-B632D10A-70F6-4DE0-9C17-B4BBBF4C314BQ47119595-75DF37DF-E3CB-4515-B539-BD8FF5CCF9DDQ48060347-FA3CE46D-A984-4C2C-AB10-1414D69CD367Q48514792-758C324C-DB98-4D1C-97E1-B06BCDEFACF6Q49804857-4FDEA93B-E611-4A29-BEB8-3E6A5DE4C0F9Q50281750-DA484843-BC5A-46E4-9B95-FDCDE371B120Q51767012-5B37AE7C-F289-4C90-A468-A5DAAB2A74CBQ52581757-B6D5509A-2090-4BAD-82F7-E449D110464C
P2860
BTS statement on malignant mesothelioma in the UK, 2007.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
BTS statement on malignant mesothelioma in the UK, 2007.
@ast
BTS statement on malignant mesothelioma in the UK, 2007.
@en
type
label
BTS statement on malignant mesothelioma in the UK, 2007.
@ast
BTS statement on malignant mesothelioma in the UK, 2007.
@en
prefLabel
BTS statement on malignant mesothelioma in the UK, 2007.
@ast
BTS statement on malignant mesothelioma in the UK, 2007.
@en
P2860
P356
P1433
P1476
BTS statement on malignant mesothelioma in the UK, 2007.
@en
P2093
British Thoracic Society Standards of Care Committee
P2860
P304
P356
10.1136/THX.2007.087619
P407
P478
62 Suppl 2
P577
2007-11-01T00:00:00Z